<DOC>
	<DOCNO>NCT01737177</DOCNO>
	<brief_summary>This prospective , multicenter phase II trial design evaluate safety activity combination Bendamustine , Lenalidomide Rituximab ( R2-B ) patient first relapsed/refractory mantle cell lymphoma ( MCL ) efficacy safety maintenance treatment Lenalidomide 18 month end R2-B ( month 7 24 ) respond induction .</brief_summary>
	<brief_title>Bendamustine/Lenalidomide/Rituximab : Combination Second-Line Therapy 1st Relapsed-Refractory MCL</brief_title>
	<detailed_description>This phase II study , non randomize , multicenter . Patients MCL refractory front line therapy first relapse enrol . The study include induction phase , consolidation phase , maintenance phase follow phase .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patient diagnosis MCL accord WHO classification ; Patient age ≥ 18 year ; Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ; Understands voluntarily sign inform consent form ; Able adhere study visit schedule protocol requirement ; Patients treat one prior regimen relapse , refractory front line therapy ; front line consolidation autologous stem cell transplantation consider part first line therapy ; Patient least one site measurable nodal disease baseline ≥ 2.0 cm long transverse diameter determine CT scan ( MRI allow CT scan perform ) . Note : Patients bone marrow involvement eligible ; Adequate haematological count : ANC &gt; 1.5 x 109/L platelet count &gt; 75 x 109/L unless due bone marrow involvement MCL ; Conjugated bilirubin 2 x ULN unless due liver involvement MCL ; Alkaline phosphatase transaminases 2 x ULN unless due liver involvement MCL ; Creatinine clearance ≥ 30 ml/min ; dose reduction Lenalidomide patient creatinine clearance ≥ 30 mL/min &lt; 50 mL/min plan ; Written inform consent obtain patient prior studyspecific screening procedure ; Patient ability swallow capsule tablet ; Life expectancy ≥ 6 month ; Disease free prior malignancy ( part MCL ) exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast ; Patients receive experimental drug use experimental medical device within 4 week plan start treatment . Concurrent participation nontreatment study allow , interfere participation study ; Patient history CNS involvement lymphoma ; Patients previous history malignancy ( part MCL ) ≤ 3 year study accrual exception currently treat basal cell squamous cell carcinoma skin , carcinoma `` situ '' cervix ; History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance ; Patient concurrent severe and/or uncontrolled medical condition ( ) ( e.g. , uncontrolled diabetes mellitus , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol ; Creatinine clearance &lt; 30 ml/min ; Patient know history HIV seropositivity ; Patient active HBV hepatitis . The following category HBV positive patient non evidence active hepatitis may consider study treat R2B ( see also Section 8.1.8 ) : patient HBsAg + HBV DNA &lt; 2000 UI/ml ( inactive carrier ) ; HBV DNA &gt; 2000 UI/ml criterion exclusion ; patient HBsAg HBsAb + ; patient HBsAg HBcAb + Patients HCV active hepatitis exclude study . Patient evidence active hepatitis and/or advance chronic liver disease accord liver biopsy fibroscan evaluation may include study Patients receive previous treatment either Bendamustine and/or Lenalidomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>MCL</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>RELAPSED-REFRACTORY</keyword>
</DOC>